TY - JOUR
T1 - Acquired factor VII deficiency associated with aplastic anaemia
T2 - correction with bone marrow transplantation
AU - Weisdorf, Daniel
AU - Hasegawa, Duane
AU - Fair, Daryl S.
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1989/3
Y1 - 1989/3
N2 - Summary. We report a patient with severe aiplastic anaemia found to have a prolonged prothrombin time due to acquired factor VII deficiency. No evidence for a factor VII inhibitor or inactivator was demonstrable. Laboratory studies identified deficiency both of factor VII activity and factor VII antigen. The factor VII deficiency persisted from clinical presentation until approximately 50 d after allogeneic marrow transplantation when restoration of factor VII activity;and antigen was noted. The patient's serum could be depleted of factor VII activity by in vitro incubation with Protein A bound to Sepharose, suggesting the presence of an IgCl or IgG containing complex able to bind factor VII, but not neutralize its procoagulant activity. A dual specificity solid phase immunoassay identified a factor VII binding immunoglobulin which was detectable throughout the course of factor VII deficiency. The concordant appearance of this factor VII reactive immunoglobulin and the factor VII deficiency suggested the pathologic role of this immunoglobulin in the aetiology of the factor VII deficiency. This factor VII binding immunoglobulin may have induced rapid plasma clearance of the factor VII molecule or, alternatively, may have modified factor VII synthesis. The immunosuppressive therapy and subsequent lymphohaematopoietic engraftment following allogeneic marrow transplant was accompanied by complete resolution of the factor VII deficiency.
AB - Summary. We report a patient with severe aiplastic anaemia found to have a prolonged prothrombin time due to acquired factor VII deficiency. No evidence for a factor VII inhibitor or inactivator was demonstrable. Laboratory studies identified deficiency both of factor VII activity and factor VII antigen. The factor VII deficiency persisted from clinical presentation until approximately 50 d after allogeneic marrow transplantation when restoration of factor VII activity;and antigen was noted. The patient's serum could be depleted of factor VII activity by in vitro incubation with Protein A bound to Sepharose, suggesting the presence of an IgCl or IgG containing complex able to bind factor VII, but not neutralize its procoagulant activity. A dual specificity solid phase immunoassay identified a factor VII binding immunoglobulin which was detectable throughout the course of factor VII deficiency. The concordant appearance of this factor VII reactive immunoglobulin and the factor VII deficiency suggested the pathologic role of this immunoglobulin in the aetiology of the factor VII deficiency. This factor VII binding immunoglobulin may have induced rapid plasma clearance of the factor VII molecule or, alternatively, may have modified factor VII synthesis. The immunosuppressive therapy and subsequent lymphohaematopoietic engraftment following allogeneic marrow transplant was accompanied by complete resolution of the factor VII deficiency.
UR - http://www.scopus.com/inward/record.url?scp=0024553732&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024553732&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2141.1989.tb04299.x
DO - 10.1111/j.1365-2141.1989.tb04299.x
M3 - Article
C2 - 2649142
AN - SCOPUS:0024553732
SN - 0007-1048
VL - 71
SP - 409
EP - 413
JO - British journal of haematology
JF - British journal of haematology
IS - 3
ER -